Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Infinity Pharmaceuticals and MedImmune have announced that the US Patent and Trademark Office has issued a patent for the companies’ heat shock protein 90 inhibitors.
Subscribe to our email newsletter
This patent includes composition of matter, pharmaceutical composition, method of treatment, and synthetic method claims directed to heat shock protein 90 (Hsp90) inhibitor and other hydroquinone-containing ansamycin analogues.
IPI-504, the companies’ lead Hsp90 inhibitor, is currently being evaluated in two separate multi-center clinical trials in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas, and in patients with non-small cell lung cancer. The patent is owned by Infinity and is co-exclusively licensed to MedImmune pursuant to the terms of the parties’ collaboration agreement.
Infinity and MedImmune also announced that the European Medicines Agency’s Committee for Orphan Medicinal Products has granted IPI-504 orphan drug designation for the treatment of GIST.